Alumis公司宣布,其研究药物Envudeucitinib在两项临床试验中表现出强大的皮肤清除能力。从治疗的第16周开始,直至第24周,该药物持续达到了高标准的临床应答阈值,显示出显著且持久的疗效。
Alumis公司宣布,其研究药物Envudeucitinib在两项临床试验中表现出强大的皮肤清除能力。从治疗的第16周开始,直至第24周,该药物持续达到了高标准的临床应答阈值,显示出显著且持久的疗效。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.